FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004112811> ?p ?o ?g. }

• W3004112811 abstract "ABSTRACT Background Brivanib (B) is an oral once daily selective dual inhibitor of FGF and VEGF signaling with preclinical activity against various tumor types. An RDT assessed B in pts with advanced solid tumors; data showing activity in sarcoma pts were reported previously, and data for the OC pts are presented here. Methods OC pts progressing after previous treatment received open-label B 800 mg QD for a 12-wk lead-in period and were assessed by CT/MRI. Pts with complete (CR) or partial response (PR) continued on open-label B, those with progressive disease (PD) went off study. Pts with stable disease (SD) were randomized 1:1 to B or placebo (P) until PD or intolerance. Pts with PD on P could crossover to open-label B. Endpoints included progression-free survival (PFS) in randomized pts, objective response rate (ORR), disease control rate (DCR = ORR + SD), and safety. Results One hundred twenty-six pts (63% with >3 prior systemic regimens; 88% FGF2+ by IHC) entered 12-wk lead-in and received B. At wk 12, 12 pts had PR and 43 pts had SD (ORR 10%; DCR 44%). Three of 18 pts pretreated with bevacizumab (BEV) achieved PR at wk 12. After 12 wks, 49 continued on the study, 10 with PR remained on open-label B; and 39 were randomized to either B (n = 19) or P (n = 20). Two pts with PR were randomized in error. Among randomized pts (n = 39), median PFS was 4 mo for B vs 2 mo for P with HR of 0.54 (90% CI: 0.28-1.03;p = 0.11). Among randomized FGF2+ pts (n = 36), HR was 0.56 (90% CI:0.29-1.07; p = 0.14). In the randomized phase, 3 additional pts achieved PR (overall population: 15 PRs; ORR 12%). The most common (≥5%) grade ≥3 AEs were increased ALT (20%) and AST (14%), fatigue (12%), hyponatremia (9%), asthenia (7%), diarrhea (7%), hypertension (7%), abdominal pain (6%), and decreased appetite (6%). Discontinuation due to treatment-related AE occurred in 13% of pts. Conclusions The observed PFS prolongation with B vs P, ORR and DCR in this RDT indicate clinical activity of B in pts with heavily pretreated OC, including those with prior BEV. The high frequency of FGF2+ pts precluded the assessment of FGF2 as a predictive biomarker. The safety profile was acceptable. These results support further investigation of B in OC, potentially in pts with prior BEV. Disclosure S.B. Kaye: Consultant for Astra Zeneca, Clovis, GSK, J&J, Pfizer Roche advisory boards Received payment from Roche for development of educational presentations L. Siu: Received research funding from Bristol-Myers Squibb J. Jassem: Advisory Board Member for Bristol-Myers Squibb C.M. Rudin: Consultancy for Oncothyreon P.J. O'Dwyer: Research funding and honorarium from Bristol-Myers Squibb Company. C. Baudelet: Employment and stock ownership of Bristol-Myers Squibb Company. A. Chen: Employment and stock ownership of Bristol-Myers Squibb Company. M.J. Ratain: Research funding from Bristol-Myers Squibb Company All other authors have declared no conflicts of interest." @default.
• W3004112811 created "2020-02-07" @default.
• W3004112811 creator A5000204204 @default.
• W3004112811 creator A5003890551 @default.
• W3004112811 creator A5004874011 @default.
• W3004112811 creator A5006913373 @default.
• W3004112811 creator A5027865512 @default.
• W3004112811 creator A5028533192 @default.
• W3004112811 creator A5033910981 @default.
• W3004112811 creator A5043932261 @default.
• W3004112811 creator A5049524331 @default.
• W3004112811 creator A5062141441 @default.
• W3004112811 creator A5062762491 @default.
• W3004112811 creator A5068268371 @default.
• W3004112811 creator A5088891659 @default.
• W3004112811 date "2012-09-01" @default.
• W3004112811 modified "2023-10-16" @default.
• W3004112811 title "Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)" @default.
• W3004112811 doi "https://doi.org/10.1093/annonc/mds401" @default.
• W3004112811 hasPublicationYear "2012" @default.
• W3004112811 type Work @default.
• W3004112811 sameAs 3004112811 @default.
• W3004112811 citedByCount "5" @default.
• W3004112811 countsByYear W30041128112013 @default.
• W3004112811 countsByYear W30041128112015 @default.
• W3004112811 crossrefType "journal-article" @default.
• W3004112811 hasAuthorship W3004112811A5000204204 @default.
• W3004112811 hasAuthorship W3004112811A5003890551 @default.
• W3004112811 hasAuthorship W3004112811A5004874011 @default.
• W3004112811 hasAuthorship W3004112811A5006913373 @default.
• W3004112811 hasAuthorship W3004112811A5027865512 @default.
• W3004112811 hasAuthorship W3004112811A5028533192 @default.
• W3004112811 hasAuthorship W3004112811A5033910981 @default.
• W3004112811 hasAuthorship W3004112811A5043932261 @default.
• W3004112811 hasAuthorship W3004112811A5049524331 @default.
• W3004112811 hasAuthorship W3004112811A5062141441 @default.
• W3004112811 hasAuthorship W3004112811A5062762491 @default.
• W3004112811 hasAuthorship W3004112811A5068268371 @default.
• W3004112811 hasAuthorship W3004112811A5088891659 @default.
• W3004112811 hasBestOaLocation W30041128111 @default.
• W3004112811 hasConcept C126322002 @default.
• W3004112811 hasConcept C141071460 @default.
• W3004112811 hasConcept C142724271 @default.
• W3004112811 hasConcept C168563851 @default.
• W3004112811 hasConcept C203092338 @default.
• W3004112811 hasConcept C204787440 @default.
• W3004112811 hasConcept C27081682 @default.
• W3004112811 hasConcept C2776694085 @default.
• W3004112811 hasConcept C2777802072 @default.
• W3004112811 hasConcept C2778715236 @default.
• W3004112811 hasConcept C71924100 @default.
• W3004112811 hasConcept C90924648 @default.
• W3004112811 hasConceptScore W3004112811C126322002 @default.
• W3004112811 hasConceptScore W3004112811C141071460 @default.
• W3004112811 hasConceptScore W3004112811C142724271 @default.
• W3004112811 hasConceptScore W3004112811C168563851 @default.
• W3004112811 hasConceptScore W3004112811C203092338 @default.
• W3004112811 hasConceptScore W3004112811C204787440 @default.
• W3004112811 hasConceptScore W3004112811C27081682 @default.
• W3004112811 hasConceptScore W3004112811C2776694085 @default.
• W3004112811 hasConceptScore W3004112811C2777802072 @default.
• W3004112811 hasConceptScore W3004112811C2778715236 @default.
• W3004112811 hasConceptScore W3004112811C71924100 @default.
• W3004112811 hasConceptScore W3004112811C90924648 @default.
• W3004112811 hasLocation W30041128111 @default.
• W3004112811 hasOpenAccess W3004112811 @default.
• W3004112811 hasPrimaryLocation W30041128111 @default.
• W3004112811 hasRelatedWork W1978028546 @default.
• W3004112811 hasRelatedWork W1984022925 @default.
• W3004112811 hasRelatedWork W1986004507 @default.
• W3004112811 hasRelatedWork W2000651446 @default.
• W3004112811 hasRelatedWork W2249979977 @default.
• W3004112811 hasRelatedWork W2315662264 @default.
• W3004112811 hasRelatedWork W2330947991 @default.
• W3004112811 hasRelatedWork W2402208612 @default.
• W3004112811 hasRelatedWork W2789999596 @default.
• W3004112811 hasRelatedWork W2793700974 @default.
• W3004112811 hasRelatedWork W2994334473 @default.
• W3004112811 hasRelatedWork W2998854237 @default.
• W3004112811 hasRelatedWork W3000022437 @default.
• W3004112811 hasRelatedWork W3000523453 @default.
• W3004112811 hasRelatedWork W3000612013 @default.
• W3004112811 hasRelatedWork W3005077603 @default.
• W3004112811 hasRelatedWork W3006202513 @default.
• W3004112811 hasRelatedWork W302431027 @default.
• W3004112811 hasRelatedWork W3083312408 @default.
• W3004112811 hasRelatedWork W3129208430 @default.
• W3004112811 isParatext "false" @default.
• W3004112811 isRetracted "false" @default.
• W3004112811 magId "3004112811" @default.
• W3004112811 workType "article" @default.